Esomeprazole With Sildenafil Citrate in Women With Early-onset Preeclampsia
Status:
Recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
Previous studies have shown that expectant management of preeclampsia in the context of
extreme prematurity may improve perinatal outcomes. Indeed, it has been estimated that for
each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is
a nonlinear corresponding gain of 1% in fetal survival. In this study, we evaluate the use of
Esomeprazole alone or with Sildenafil Citrate for the treatment of singleton pregnancies
complicated by preeclampsia. We hypothesized that the potential increase in uteroplacental
and fetoplacental blood flow with the use of Esomeprazole alone or with Sildenafil Citrate
may be associated with pregnancy prolongation (the primary study outcome) and improved
maternal and perinatal outcomes.